Proprietary Herbicide Active Ingredient

The molecule after glyphosate.

ZERAXEN is a patent-protected herbicide active ingredient engineered for next-generation GMO crop systems — selective, residue-free, and built for regulatory approval.

Request Confidential Briefing View molecule data →
Novel Mode of Action
GMO-ready Trait compatible
EU MRL Below threshold
Patent Protected IP
The Problem

Glyphosate's window is closing.

Glyphosate faces mounting regulatory pressure across the EU, UK, and key emerging markets. Its authorization is under active review and renewal is contested.

The industry needs a drop-in successor — compatible with existing GMO trait platforms, with a cleaner residue profile and a viable path to regulatory approval.

No approved successor currently exists in late-stage global development. The transition window is open now.

⚖
Regulatory pressure
EU authorization under active review. Renewal contested across member states and the UK.
⚠
Resistance crisis
Glyphosate-resistant weed species confirmed in 50+ species worldwide, reducing efficacy each season.
◎
No successor in sight
No molecule is currently in late-stage development with comparable GMO-platform compatibility.
→
Market exposure
Billions in GMO seed licensing revenue depends on a viable, approvable herbicide partner molecule.
The Molecule

Engineered for the post-glyphosate era.

ZERAXEN was designed from the ground up for compatibility with current GMO tolerance traits — without requiring re-engineering of the seed platform. Its novel mode of action bypasses existing resistance mechanisms.

Mode of Action
HPPD Inhibitor
Novel chemical class. Bypasses existing glyphosate resistance mechanisms across all major weed families.
Crop Selectivity
GMO-trait compatible
Broad-spectrum weed control. Engineered for direct pairing with existing GMO tolerance platforms.
Residue Profile
Below EU MRL threshold
Residue-free at harvest under trial conditions. Clean regulatory profile for EU and global markets.
Development Status
Synthesis & characterization Complete
Greenhouse selectivity trials Complete
Field validation trials In progress
Regulatory pre-submission dossier In preparation

Patent-protected.
Available for exclusive licensing or acquisition.

NDA available upon request  ·  Full technical dossier on file  ·  zeraxen.com

Request Confidential Briefing
Why Now

The transition window is open.

The regulatory clock is running. The first molecule to achieve late-stage validation with GMO platform compatibility will define the next 30 years of herbicide licensing.

ZERAXEN is patent-protected and available today for exclusive licensing or outright acquisition. An NDA and complete technical dossier are available upon request.

01
EU authorization under review
Glyphosate renewal is actively contested. Regulatory timeline creates urgency for industry succession planning.
02
No successor in late-stage development
No molecule currently approaching approval with comparable GMO-platform compatibility and residue profile.
03
Resistance gap is widening
50+ confirmed glyphosate-resistant weed species, with new biotypes emerging each season globally.
04
Exclusive window is open now
ZERAXEN is available for exclusive global licensing or acquisition. First mover terms available.
Contact

Request a confidential briefing.

Send us a message and we will respond within 48 hours. A full technical dossier and NDA are available for qualified parties.

Licensing & Partnerships
For partnership or licensing inquiries:
[email protected]
Press & Media
For press, media and analyst inquiries:
[email protected]
⊕

NDA first, details after. All technical documentation, synthesis data, and field trial results are shared exclusively under a mutual NDA.

Terms of Engagement
ZERAXEN is available for exclusive global licensing, regional co-development, or outright IP acquisition. Milestone-based structures available.